Home » Authors » Kim Coghill

Articles by Kim Coghill

Applied Genetics Raises $15.2M For AAV Technology, Products

Dec. 4, 2003

Applied Genetics Raises $15.2M For AAV Technology, Products

Dec. 4, 2003

Stressgen, Roche Add New Indications To Collaboration

Dec. 3, 2003

Stressgen, Roche Add New Indications To Collaboration

Dec. 3, 2003

Neurogen Assured $42M, Could Get Much More In Merck Alliance

Dec. 2, 2003

Neurogen Corp.'s stock gained 64 percent Monday on news that it entered an exclusive worldwide alliance with Merck & Co. Inc. to discover and develop pain medications that target the vanilloid receptor, a key integrator of pain signals in the nervous system. (BioWorld Today)

Neurogen Assured $42M, Could Get Much More In Merck Alliance

Dec. 2, 2003

Neurogen Corp.'s stock gained 64 percent Monday on news that it entered an exclusive worldwide alliance with Merck & Co. Inc. to discover and develop pain medications that target the vanilloid receptor, a key integrator of pain signals in the nervous system. (BioWorld Today)

Medicare Bill To White House; Most Applaud New Regulations

Dec. 1, 2003

Medicare Bill To White House; Most Applaud New Regulations

Dec. 1, 2003

Amylin, Lilly Release Data From Third Phase III Trial Of Exenatide

Nov. 26, 2003

Amylin, Lilly Release Data From Third Phase III Trial Of Exenatide

Nov. 26, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...